Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)

Trial Profile

OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Perindopril/amlodipine
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms OLMAML
  • Sponsors Menarini
  • Most Recent Events

    • 25 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
    • 24 May 2016 Results (post hoc analysis of a substudy) comparing effect of olmesartan/amlodipine versus perindopril/amlodipine published in the American Journal of Hypertension.
    • 15 Jun 2015 Primary endpoint Office diastolic blood pressure has been met as per results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top